← Back to Clinical Trials
Recruiting NCT06855446

NCT06855446 Interactive Mirroring Games wIth sOcial Robot (IOGIOCO) and Robotic System Adapted Into a Clinical Scale (RISCALE)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06855446
Status Recruiting
Phase
Sponsor Fondazione Don Carlo Gnocchi ETS
Condition Autism Spectrum Disorder
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2023-07-14
Primary Completion 2025-04

Eligibility & Interventions

Sex All sexes
Min Age 18 Months
Max Age 72 Months
Study Type INTERVENTIONAL
Interventions
Intervention with social robot NAOTreatment as usual

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2023-07-14 with a primary completion date of 2025-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Background: The importance of early intervention in Autism Spectrum Disorders (ASD) has been widely demonstrated, and developmental trajectories in ASD highlight the importance of nonverbal communication, such as intransitive gesture production, as a possible positive prognostic factor for language development. The use of technological tools in the therapy of individuals with ASD has also become increasingly important due to their increased engagement and responsiveness to technological objects, such as robots. Materials and methods: We developed a training protocol using the humanoid robot NAO, called IOGIOCO (Interactive mirroring Games wIth sOCial rObot), based on the use of intransitive gestures embedded in naturalistic dialogues, stimulating a triadic interaction between child, robot and therapist. The training is divided into six levels; the first 2 levels were called "familiarization levels," and the other 4 were "training levels". The technological setup includes different complexity levels, from mirroring tasks to building spontaneous interactions. We previously tested the protocol on 10 preschool children with ASD (aged 2-6 years) in a pilot study founding promising results (Annunziata et al,2024). We therefore developed a Randomized Controlled Trial to test the efficacy of this intervention. The project is to be divided into three phases. 1. Establishment, adaptation, and subsequent validation of the video recording setting, accompanied by the identification of the quantitative parameters discernible through technological tools (ECSP-I\_rob) on a sample of typically developing children aged between 18 and 24 months. 2. Setting, adaptation, and and subsequently validate the video recording setting with the measurement of the quantitative parameters detectable through technological tools (ECSP-I\_rob) on a sample of children with Autism Spectrum Disorder under the age of 72 months. 3\) Initiate training with NAO on a group of children with ASD aged 24-72 months with pre- and post-treatment ECSP-I administration Objectives 1. Evaluate the effectiveness of the robot-based intervention on social-communicative skills and in the acquisition of intransitive gestures used for communicative purposes using the ECSP-I and the MacArthur questionnaire as outcome measures. 2. Identify and describe measurable parameters of "social" interaction within the rehabilitation session with NAO and the operator. Furthermore, it is essential to verify their evolution and differences at the beginning and end of treatment and between the different social partners. We aim to enroll 20 typical children aged 18-24 months to validate the ECSP-I robot. For the phase 2 and 3 we aim to enroll 20 ASD preschool children with an ASD diagnosis according to DSM-5 criteria (confirmed by ADOS-2). We will test them at T0 (Griffiths-III, ABAS-II, MacArthur-Bates number of gestures) and randomly assign them to two groups, G1 and G2, according to a cross-over design. After T0 assessment, Group 1 will undergo to a 12-weekly-session training with the social robot NAO, while G2 will continue the therapy as usual. We will assess again at T1 (after 12 sessions, through ABAS-II and MacArthur-Bates), subsequently G1 will be included in a follow-up group, while the G2 will undergo to the social robot intervention. We will assess all the participants at T2; we will moreover administrate a satisfaction questionnaire to parents.

Eligibility Criteria

Inclusion Criteria: * Autism Spectrum Disorder diagnosis Exclusion Criteria: * known genetic or metabolic diseases

Contact & Investigator

Central Contact

Chiara Fanciullacci

✉ ctu@dongnocchi.it

📞 0039055 7393653

Frequently Asked Questions

Who can join the NCT06855446 clinical trial?

This trial is open to participants of all sexes, aged 18 Months or older, up to 72 Months, studying Autism Spectrum Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06855446 currently recruiting?

Yes, NCT06855446 is actively recruiting participants. Contact the research team at ctu@dongnocchi.it for enrollment information.

Where is the NCT06855446 trial being conducted?

This trial is being conducted at Milan, Italy.

Who is sponsoring the NCT06855446 clinical trial?

NCT06855446 is sponsored by Fondazione Don Carlo Gnocchi ETS. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology